The effect of ?3 fatty acids supplementation in elite male athletes

The effect of ?3 fatty acids supplementation on levels of PPAR? and UCP2 genes expression, serum level of UCP2 protein, metabolic status, and appetite in elite male athletes: a randomized control trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190625044008N1

Enrollment

Registered

2019-12-19

Start date

2019-10-02

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention 1: Intervention group: soft gel supplement fatty acid ?3 daily 2 soft gel, dose of 1 g with lunch and dinner for 3 weeks. Intervention 2: Control group: soft gel placebo (paraffin) daily

Eligibility

Sex/Gender

Male

Age

20 Years to 30 Years

Inclusion criteria

Inclusion criteria: No history of chronic and/or blood coagulation diseases Range of BMI of 18.5 to 25 kg / m 2 Willingness to participate in the study Age 20– 30 years

Exclusion criteria

Exclusion criteria: Received ?3 fatty acids supplements in last month

Design outcomes

Primary

Measure	Time frame
Anthropometric measures. Timepoint: Baseline and 3 weeks after intervention. Method of measurement: Measurement of height and weight without shoes and with minimum clothes on, by Seca stadiometer and scale, respectively. Calculation of body mass index (BMI) by dividing weight (Kg) by height squared (m2).;Body composition. Timepoint: Baseline and 3 weeks after intervention. Method of measurement: Bioelectrical Impedance Analysis (BIA) to determine Fat mass (FM), Fat free mass (FFM), and Body water (BW).;Resting metabolic rate. Timepoint: Baseline and 3 weeks after intervention. Method of measurement: Indirect calorimetry.;Blood pressure. Timepoint: Baseline and 3 weeks after intervention. Method of measurement: Stethoscope.;Appetite status. Timepoint: Baseline and 3 weeks after intervention. Method of measurement: Visual analogue scale.;Serum UCP2 protein level. Timepoint: Baseline and 3 weeks after intervention. Method of measurement: ELISA.;Uncoupling protein2 gene expression. Timepoint: Baseline and 3 weeks after intervention. Method of measurement: Real-time polymerase chain reaction (PCR).;Peroxisome proliferator-activated receptors gamma gene expression. Timepoint: Baseline and 3 weeks after intervention. Method of measurement: Real-time polymerase chain reaction (PCR).;Serum triglycerides. Timepoint: Baseline and 3 weeks after intervention. Method of measurement: Autoanalyzer kit.;Serum low density lipoprotein cholesterol. Timepoint: Baseline and 3 weeks after intervention. Method of measurement: Calculation of LDL-cholesterol by Friedewald equation.;Serum high density lipoprotein cholesterol. Timepoint: Baseline and 3 weeks after intervention. Method of measurement: Autoanalyzer kit.;Total cholesterol. Timepoint: Baseline and 3 weeks after intervention. Method of measurement: Autoanalyzer kit.	—

Measure

Time frame

Anthropometric measures. Timepoint: Baseline and 3 weeks after intervention. Method of measurement: Measurement of height and weight without shoes and with minimum clothes on, by Seca stadiometer and scale, respectively. Calculation of body mass index (BMI) by dividing weight (Kg) by height squared (m2).;Body composition. Timepoint: Baseline and 3 weeks after intervention. Method of measurement: Bioelectrical Impedance Analysis (BIA) to determine Fat mass (FM), Fat free mass (FFM), and Body water (BW).;Resting metabolic rate. Timepoint: Baseline and 3 weeks after intervention. Method of measurement: Indirect calorimetry.;Blood pressure. Timepoint: Baseline and 3 weeks after intervention. Method of measurement: Stethoscope.;Appetite status. Timepoint: Baseline and 3 weeks after intervention. Method of measurement: Visual analogue scale.;Serum UCP2 protein level. Timepoint: Baseline and 3 weeks after intervention. Method of measurement: ELISA.;Uncoupling protein2 gene expression. Timepoint: Baseline and 3 weeks after intervention. Method of measurement: Real-time polymerase chain reaction (PCR).;Peroxisome proliferator-activated receptors gamma gene expression. Timepoint: Baseline and 3 weeks after intervention. Method of measurement: Real-time polymerase chain reaction (PCR).;Serum triglycerides. Timepoint: Baseline and 3 weeks after intervention. Method of measurement: Autoanalyzer kit.;Serum low density lipoprotein cholesterol. Timepoint: Baseline and 3 weeks after intervention. Method of measurement: Calculation of LDL-cholesterol by Friedewald equation.;Serum high density lipoprotein cholesterol. Timepoint: Baseline and 3 weeks after intervention. Method of measurement: Autoanalyzer kit.;Total cholesterol. Timepoint: Baseline and 3 weeks after intervention. Method of measurement: Autoanalyzer kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSara Moradi

Tabriz University of Medical Sciences

saramoradi678@gmail.com+98 41 3441 5282

Outcome results